Arrowstreet Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,159
| Closed | -$367K | – | 1981 |
|
|
2025
Q4 | $367K | Buy |
+2,159
| New | +$331K | ﹤0.01% | 1720 |
|
|
2024
Q4 | – | Sell |
-76,306
| Closed | -$8.5M | – | 1863 |
|
|
2024
Q3 | $8.5M | Buy |
76,306
+32,069
| +72% | +$3.51M | 0.01% | 803 |
|
|
2024
Q2 | $4.72M | Buy |
+44,237
| New | +$4.86M | ﹤0.01% | 859 |
|
|
2023
Q4 | – | Sell |
-119,101
| Closed | -$15.4M | – | 1482 |
|
|
2023
Q3 | $15.4M | Sell |
119,101
-186,190
| -61% | -$24.8M | 0.02% | 437 |
|
|
2023
Q2 | $37.8M | Sell |
305,291
-239,249
| -44% | -$32.2M | 0.05% | 289 |
|
|
2023
Q1 | $79.7M | Sell |
544,540
-139,977
| -20% | -$20.7M | 0.1% | 191 |
|
|
2022
Q4 | $109M | Buy |
684,517
+182,721
| +36% | +$26.8M | 0.15% | 151 |
|
|
2022
Q3 | $66.9M | Buy |
501,796
+497,016
| +10,398% | +$75.6M | 0.1% | 190 |
|
|
2022
Q2 | $746K | Buy |
+4,780
| New | +$736K | ﹤0.01% | 996 |
|
|
2021
Q4 | – | Sell |
-24,900
| Closed | -$3.24M | – | 1575 |
|
|
2021
Q3 | $3.24M | Sell |
24,900
-212,952
| -90% | -$32.2M | ﹤0.01% | 1039 |
|
|
2021
Q2 | $42.3M | Buy |
237,852
+162,037
| +214% | +$28.1M | 0.05% | 368 |
|
|
2021
Q1 | $12.5M | Buy |
+75,815
| New | +$12.5M | 0.02% | 774 |
|
|
2020
Q3 | – | Sell |
-123,397
| Closed | -$13.6M | – | 2415 |
|
|
2020
Q2 | $13.6M | Sell |
123,397
-30,167
| -20% | -$3.34M | 0.03% | 656 |
|
|
2020
Q1 | $15.3M | Sell |
153,564
-447,688
| -74% | -$57.9M | 0.04% | 364 |
|
|
2019
Q4 | $89.8M | Buy |
601,252
+165,144
| +38% | +$22.5M | 0.21% | 92 |
|
|
2019
Q3 | $55.9M | Buy |
436,108
+177,048
| +68% | +$23.7M | 0.13% | 170 |
|
|
2019
Q2 | $36.9M | Sell |
259,060
-50,935
| -16% | -$6.85M | 0.08% | 237 |
|
|
2019
Q1 | $44.3M | Buy |
309,995
+307,695
| +13,378% | +$40.1M | 0.1% | 205 |
|
|
2018
Q4 | $285K | Sell |
2,300
-54,767
| -96% | -$8.12M | ﹤0.01% | 1199 |
|
|
2018
Q3 | $9.6M | Buy |
57,067
+50,567
| +778% | +$8.7M | 0.02% | 418 |
|
|
2018
Q2 | $1.12M | Buy |
+6,500
| New | +$1.06M | ﹤0.01% | 780 |
|
|
2017
Q4 | – | Sell |
-18,800
| Closed | -$2.75M | – | 1324 |
|
|
2017
Q3 | $2.75M | Sell |
18,800
-16,700
| -47% | -$2.53M | 0.01% | 620 |
|
|
2017
Q2 | $5.52M | Buy |
+35,500
| New | +$5.43M | 0.02% | 450 |
|
|
2016
Q3 | – | Sell |
-24,800
| Closed | -$3.5M | – | 1554 |
|
|
2016
Q2 | $3.5M | Buy |
+24,800
| New | +$3.66M | 0.01% | 679 |
|
|
2015
Q4 | – | Sell |
-151,100
| Closed | -$20.1M | – | 1493 |
|
|
2015
Q3 | $20.1M | Buy |
151,100
+56,300
| +59% | +$9.69M | 0.1% | 211 |
|
|
2015
Q2 | $16.7M | Buy |
+94,800
| New | +$17M | 0.09% | 198 |
|
|
2014
Q4 | – | Sell |
-51,951
| Closed | -$8.34M | – | 1281 |
|
|
2014
Q3 | $8.34M | Buy |
51,951
+46,048
| +780% | +$7.08M | 0.04% | 307 |
|
|
2014
Q2 | $868K | Sell |
5,903
-30,148
| -84% | -$4.18M | ﹤0.01% | 739 |
|
|
2014
Q1 | $5M | Buy |
+36,051
| New | +$5.43M | 0.03% | 446 |
|
Other funds holding JAZZ
VPM
VCM
EC
Arrowstreet Capital's JAZZ Position: Q1 2026 in Review
Arrowstreet Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,159 shares — an estimated $367K sold.
Arrowstreet Capital first reported a position in JAZZ in Q1 2014 and held it in 29 quarters. The position peaked at $109M in Q4 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Arrowstreet Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Arrowstreet Capital sold 2,159 Jazz Pharmaceuticals shares in Q1 2026, an estimated $367K.
- Arrowstreet Capital first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 29 quarters.
- Arrowstreet Capital's Jazz Pharmaceuticals position peaked at $109M in Q4 2022.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.